Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1996 Jun;148(6):2073–2082.

Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

T A Järvinen 1, J Kononen 1, M Pelto-Huikko 1, J Isola 1
PMCID: PMC1861630  PMID: 8669491

Abstract

The role of molecular markers predicting the response to cytotoxic chemotherapy is not established. A potential predictive factor, topoisomerase IIalpha, is a target for certain cytotoxic drugs, and its concentration has been shown to correlate with chemosensitivity in vitro. We evaluated expression of topo IIalpha immunohistochemically in 230 breast cancer samples and studied its association with known clinicopathological factors and factors previously shown to predict response to cytotoxic drugs. Topo IIalpha protein expression was found in 0.6 to 39.4% (10.6 +/- 7.9%, mean +/- SD) of breast carcinoma cells, whereas expression was undetectable in nonmalignant breast epithelium. Topo IIalpha protein expression correlated well with semi-quantitative mRNA in situ hybridization (P = 0.007). A significant association was found between the proportion of topo-IIalpha-positive cells and low estrogen and progesterone receptor content (P<0.0001), high grade (P<0.0001), DNA aneuploidy (P=0.003), and c-erbB-2 oncoprotein overexpression (P<0.0001). Topo IIalpha expression was not associated with clinical variables, such as age of the patient, primary tumor size, or axillary nodal status. A highly significant linear correlation was found between topo IIalpha and tumor proliferation rate (S-phase fraction, r=0.46; P<0.0001). Because hormone receptors, grade, and ploidy are associated with tumor proliferation rate, topo IIalpha expression was adjusted for S-phase fraction to reveal the proliferation-independent clinopathological associations. According to the analysis of co-variance, only aneuploidy (P=0.0003) and c-erb-2 overexpression (P=0.01) were associated with proliferation-adjusted expression of topo IIalpha. In conclusion, the close association of Topo IIalpha with other potential predictive factors (tumor proliferation rate, c-erbB-2 oncoprotein) suggests that topo IIalpha, having a defined role as a target for cytotoxic drugs, may be a valuable predictor of response to chemotherapy.

Full text

PDF
2073

Images in this article

2077Figure 1
on p.2077
2078Figure 2
on p.2078
2078Figure 3
on p.2078
2079Figure 5
on p.2079

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allred D. C., Clark G. M., Tandon A. K., Molina R., Tormey D. C., Osborne C. K., Gilchrist K. W., Mansour E. G., Abeloff M., Eudey L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992 Apr;10(4):599–605. doi: 10.1200/JCO.1992.10.4.599. [DOI] [PubMed] [Google Scholar]
  2. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boege F., Andersen A., Jensen S., Zeidler R., Kreipe H. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. Am J Pathol. 1995 Jun;146(6):1302–1308. [PMC free article] [PubMed] [Google Scholar]
  4. Brown G. A., McPherson J. P., Gu L., Hedley D. W., Toso R., Deuchars K. L., Freedman M. H., Goldenberg G. J. Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 1995 Jan 1;55(1):78–82. [PubMed] [Google Scholar]
  5. Chen A. Y., Liu L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 1994;34:191–218. doi: 10.1146/annurev.pa.34.040194.001203. [DOI] [PubMed] [Google Scholar]
  6. Dagerlind A., Friberg K., Bean A. J., Hökfelt T. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry. 1992 Aug;98(1):39–49. doi: 10.1007/BF00716936. [DOI] [PubMed] [Google Scholar]
  7. Danks M. K., Qiu J., Catapano C. V., Schmidt C. A., Beck W. T., Fernandes D. J. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol. 1994 Nov 1;48(9):1785–1795. doi: 10.1016/0006-2952(94)90465-0. [DOI] [PubMed] [Google Scholar]
  8. Davies S. M., Robson C. N., Davies S. L., Hickson I. D. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem. 1988 Nov 25;263(33):17724–17729. [PubMed] [Google Scholar]
  9. Elledge R. M., McGuire W. L., Osborne C. K. Prognostic factors in breast cancer. Semin Oncol. 1992 Jun;19(3):244–253. [PubMed] [Google Scholar]
  10. Froelich-Ammon S. J., Osheroff N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem. 1995 Sep 15;270(37):21429–21432. doi: 10.1074/jbc.270.37.21429. [DOI] [PubMed] [Google Scholar]
  11. Fry A. M., Chresta C. M., Davies S. M., Walker M. C., Harris A. L., Hartley J. A., Masters J. R., Hickson I. D. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 1991 Dec 15;51(24):6592–6595. [PubMed] [Google Scholar]
  12. Gusterson B. A., Gelber R. D., Goldhirsch A., Price K. N., Säve-Söderborgh J., Anbazhagan R., Styles J., Rudenstam C. M., Golouh R., Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul;10(7):1049–1056. doi: 10.1200/JCO.1992.10.7.1049. [DOI] [PubMed] [Google Scholar]
  13. Harker W. G., Slade D. L., Parr R. L., Feldhoff P. W., Sullivan D. M., Holguin M. H. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr 15;55(8):1707–1716. [PubMed] [Google Scholar]
  14. Hellemans P., van Dam P. A., Geyskens M., van Oosterom A. T., Buytaert P., Van Marck E. Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol. 1995 Feb;48(2):147–150. doi: 10.1136/jcp.48.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hietanen P., Blomqvist C., Wasenius V. M., Niskanen E., Franssila K., Nordling S. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer. 1995 May;71(5):1029–1032. doi: 10.1038/bjc.1995.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Holden J. A., Rolfson D. H., Wittwer C. T. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry. 1990 Feb 27;29(8):2127–2134. doi: 10.1021/bi00460a024. [DOI] [PubMed] [Google Scholar]
  17. Holden J. A., Rolfson D. H., Wittwer C. T. The distribution of immunoreactive topoisomerase II Protein in human tissues and neoplasms. Oncol Res. 1992;4(4-5):157–166. [PubMed] [Google Scholar]
  18. Holden J. A., Snow G. W., Perkins S. L., Jolles C. J., Kjeldsberg C. R. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol. 1994 Oct;7(8):829–834. [PubMed] [Google Scholar]
  19. Holm C. Coming undone: how to untangle a chromosome. Cell. 1994 Jul 1;77(7):955–957. doi: 10.1016/0092-8674(94)90433-2. [DOI] [PubMed] [Google Scholar]
  20. Houlbrook S., Addison C. M., Davies S. L., Carmichael J., Stratford I. J., Harris A. L., Hickson I. D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer. 1995 Dec;72(6):1454–1461. doi: 10.1038/bjc.1995.529. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kallioniemi O. P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry. 1988 Mar;9(2):164–169. doi: 10.1002/cyto.990090211. [DOI] [PubMed] [Google Scholar]
  22. Kallioniemi O. P., Holli K., Visakorpi T., Koivula T., Helin H. H., Isola J. J. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991 Nov 11;49(5):650–655. doi: 10.1002/ijc.2910490504. [DOI] [PubMed] [Google Scholar]
  23. Kaufmann S. H., Karp J. E., Jones R. J., Miller C. B., Schneider E., Zwelling L. A., Cowan K., Wendel K., Burke P. J. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood. 1994 Jan 15;83(2):517–530. [PubMed] [Google Scholar]
  24. Keith W. N., Douglas F., Wishart G. C., McCallum H. M., George W. D., Kaye S. B., Brown R. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer. 1993;29A(10):1469–1475. doi: 10.1016/0959-8049(93)90022-8. [DOI] [PubMed] [Google Scholar]
  25. Kreipe H., Heidebrecht H. J., Hansen S., Röhlk W., Kubbies M., Wacker H. H., Tiemann M., Radzun H. J., Parwaresch R. A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol. 1993 Jan;142(1):3–9. [PMC free article] [PubMed] [Google Scholar]
  26. Kubo T., Kohno K., Ohga T., Taniguchi K., Kawanami K., Wada M., Kuwano M. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res. 1995 Sep 1;55(17):3860–3864. [PubMed] [Google Scholar]
  27. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  28. Muss H. B., Thor A. D., Berry D. A., Kute T., Liu E. T., Koerner F., Cirrincione C. T., Budman D. R., Wood W. C., Barcos M. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260–1266. doi: 10.1056/NEJM199405053301802. [DOI] [PubMed] [Google Scholar]
  29. O'Reilly S. M., Camplejohn R. S., Rubens R. D., Richards M. A. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer. 1992;28(2-3):681–683. doi: 10.1016/s0959-8049(05)80124-8. [DOI] [PubMed] [Google Scholar]
  30. Peacock C. S., Thompson I. W., Van Noorden S. Silver enhancement of polymerised diaminobenzidine: increased sensitivity for immunoperoxidase staining. J Clin Pathol. 1991 Sep;44(9):756–758. doi: 10.1136/jcp.44.9.756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pelto-Huikko M., Dagerlind A., Kononen J., Lundberg J. M., Villar M., Koistinaho J., Bravo R., Hökfelt T. Neuronal regulation of c-fos, c-jun, and junB immediate-early genes in rat adrenal medulla. J Neurosci. 1995 Mar;15(3 Pt 1):1854–1868. doi: 10.1523/JNEUROSCI.15-03-01854.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Ravdin P. M., Chamness G. C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene. 1995 Jun 14;159(1):19–27. doi: 10.1016/0378-1119(94)00866-q. [DOI] [PubMed] [Google Scholar]
  33. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  34. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci. 1995 Apr;20(4):156–160. doi: 10.1016/s0968-0004(00)88993-8. [DOI] [PubMed] [Google Scholar]
  35. Roca J., Wang J. C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell. 1994 May 20;77(4):609–616. doi: 10.1016/0092-8674(94)90222-4. [DOI] [PubMed] [Google Scholar]
  36. Smith K., Houlbrook S., Greenall M., Carmichael J., Harris A. L. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene. 1993 Apr;8(4):933–938. [PubMed] [Google Scholar]
  37. Sulkes A., Livingston R. B., Murphy W. K. Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst. 1979 Mar;62(3):513–515. doi: 10.1093/jnci/62.3.513. [DOI] [PubMed] [Google Scholar]
  38. Taagepera S., Rao P. N., Drake F. H., Gorbsky G. J. DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8407–8411. doi: 10.1073/pnas.90.18.8407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tsai-Pflugfelder M., Liu L. F., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T., Huebner K., Croce C. M., Wang J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177–7181. doi: 10.1073/pnas.85.19.7177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tuccari G., Rizzo A., Giuffrè G., Barresi G. Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinico-pathological features. Virchows Arch A Pathol Anat Histopathol. 1993;423(1):51–55. doi: 10.1007/BF01606432. [DOI] [PubMed] [Google Scholar]
  41. Watt P. M., Hickson I. D. Structure and function of type II DNA topoisomerases. Biochem J. 1994 Nov 1;303(Pt 3):681–695. doi: 10.1042/bj3030681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Withoff S., Smit E. F., Meersma G. J., van den Berg A., Timmer-Bosscha H., Kok K., Postmus P. E., Mulder N. H., de Vries E. G., Buys C. H. Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest. 1994 Jul;71(1):61–66. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES